104 related articles for article (PubMed ID: 16678048)
1. Antiprostasome antibodies: possible serum markers for prostate cancer metastasizing liability.
Larsson A; Ronquist G; Wülfing C; Eltze E; Bettendorf O; Carlsson L; Nilsson BO; Semjonow A
Urol Oncol; 2006; 24(3):195-200. PubMed ID: 16678048
[TBL] [Abstract][Full Text] [Related]
2. Antiprostasome antibody titres in benign and malignant prostate disease.
Minelli A; Ronquist G; Carlsson L; Mearini E; Nilsson O; Larsson A
Anticancer Res; 2005; 25(6C):4399-402. PubMed ID: 16334115
[TBL] [Abstract][Full Text] [Related]
3. Antiprostasome antibodies are not an appropriate prognostic marker for prostate cancer.
Stewart AB; Delves GH; Birch BR; Cooper AJ; Lwaleed BA
Scand J Urol Nephrol; 2009; 43(2):104-8. PubMed ID: 18979375
[TBL] [Abstract][Full Text] [Related]
4. Development of an immunoassay for serum caveolin-1: a novel biomarker for prostate cancer.
Tahir SA; Ren C; Timme TL; Gdor Y; Hoogeveen R; Morrisett JD; Frolov A; Ayala G; Wheeler TM; Thompson TC
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3653-9. PubMed ID: 14506154
[TBL] [Abstract][Full Text] [Related]
5. Serum antibodies against prostasomal clusterin in prostate cancer patients.
Ronquist KG; Carlsson L; Ronquist G; Semjonow A; Wülfing C; Larsson A
Scand J Clin Lab Invest; 2008; 68(3):219-27. PubMed ID: 17926197
[TBL] [Abstract][Full Text] [Related]
6. The antibody response to Propionibacterium acnes is an independent predictor of serum prostate-specific antigen levels in biopsy-negative men.
Shannon BA; Cohen RJ; Garrett KL
BJU Int; 2008 Feb; 101(4):429-35. PubMed ID: 17850358
[TBL] [Abstract][Full Text] [Related]
7. Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases.
Selander KS; Brown DA; Sequeiros GB; Hunter M; Desmond R; Parpala T; Risteli J; Breit SN; Jukkola-Vuorinen A
Cancer Epidemiol Biomarkers Prev; 2007 Mar; 16(3):532-7. PubMed ID: 17372249
[TBL] [Abstract][Full Text] [Related]
8. Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.
Shafer MW; Mangold L; Partin AW; Haab BB
Prostate; 2007 Feb; 67(3):255-67. PubMed ID: 17192876
[TBL] [Abstract][Full Text] [Related]
9. Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer.
Okegawa T; Nutahara K; Higashihara E
J Urol; 2008 Oct; 180(4):1342-7. PubMed ID: 18707699
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
[TBL] [Abstract][Full Text] [Related]
11. Use of human prostate-specific antigen in monitoring prostate cancer.
Kuriyama M; Wang MC; Lee CI; Papsidero LD; Killian CS; Inaji H; Slack NH; Nishiura T; Murphy GP; Chu TM
Cancer Res; 1981 Oct; 41(10):3874-6. PubMed ID: 7284995
[TBL] [Abstract][Full Text] [Related]
12. Antibody and T-cell responses specific for the androgen receptor in patients with prostate cancer.
Olson BM; McNeel DG
Prostate; 2007 Dec; 67(16):1729-39. PubMed ID: 17879963
[TBL] [Abstract][Full Text] [Related]
13. [Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer].
Sun CC; Zheng W; Kong CZ; Wang X; Yang CM
Zhonghua Nan Ke Xue; 2006 Oct; 12(10):904-5, 909. PubMed ID: 17121020
[TBL] [Abstract][Full Text] [Related]
14. Detection of prostate-specific antigen coupled to immunoglobulin M in prostate cancer patients.
Beneduce L; Prayer-Galetti T; Giustinian AM; Gallotta A; Betto G; Pagano F; Fassina G
Cancer Detect Prev; 2007; 31(5):402-7. PubMed ID: 18035503
[TBL] [Abstract][Full Text] [Related]
15. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
Klepzig M; Jonas D; Oremek GM
Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
[TBL] [Abstract][Full Text] [Related]
16. Autoantibodies to prostasomes as new markers for prostate cancer.
Nilsson BO; Carlsson L; Larsson A; Ronquist G
Ups J Med Sci; 2001; 106(1):43-9. PubMed ID: 11817562
[TBL] [Abstract][Full Text] [Related]
17. Serum inhibin--not a cause of low testosterone levels in hypogonadal prostate cancer?
Lackner JE; Maerk I; Koller A; Bieglmayer C; Marberger M; Kratzik C; Schatzl G
Urology; 2008 Nov; 72(5):1121-4. PubMed ID: 18407338
[TBL] [Abstract][Full Text] [Related]
18. Biochemical markers of bone turnover in patients with localized and metastasized prostate cancer.
Hegele A; Wahl HG; Varga Z; Sevinc S; Koliva L; Schrader AJ; Hofmann R; Olbert P
BJU Int; 2007 Feb; 99(2):330-4. PubMed ID: 17092281
[TBL] [Abstract][Full Text] [Related]
19. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase.
Xie W; Nakabayashi M; Regan MM; Oh WK
Cancer; 2007 Dec; 110(12):2709-15. PubMed ID: 17960608
[TBL] [Abstract][Full Text] [Related]
20. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
